Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 12 - 14 tags : Trial save search
Route 92 Medical Raises $111 Million in Combined Series E and Debt FinancingPlans to execute the SUMMIT MAX trial to obtain FDA clearance for the proprietary Route 92 Medical Reperfusion System
Published: 2021-12-14 (Crawled : 01:00) - biospace.com/
RWAY | $12.645 0.6% 0.59% 250K
|
|
| O: 0.94%
H: 0.0%
C: 0.0%
fda clearance trial fda clearance
Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem
Published: 2021-12-14 (Crawled : 15:30) - biospace.com/
GRTX | $0.1928 1.05% 1.04% 350K
|
Health Technology
|
| O: 105.07%
H: 22.26%
C: -4.59%
trial topline phase 3 avasopasem roman trial
Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Published: 2021-12-14 (Crawled : 15:30) - biospace.com/
CDTX | News | $0.5141 0.04% 0.04% 1.9M
|
Health Technology
|
| O: -15.03%
H: 0.36%
C: -14.8%
treatment trial therapeutics topline results positive results topline phase 3 candidemia
PharmaJet Partner Nykode Therapeutics Announces Phase 1/2 Clinical Trial With Next Generation DNA-Based COVID-19 Vaccine Candidates
Published: 2021-12-14 (Crawled : 15:00) - biospace.com/
NKTR | News | $1.415 4.04% 3.89% 1.1M
|
Health Technology
|
| O: 2.3%
H: 3.69%
C: 1.77%
covid-19 trial therapeutics covid phase 1 vaccine phase 2
Rockwell Medical Receives Important Feedback from FDA on its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion
Published: 2021-12-14 (Crawled : 14:00) - globenewswire.com
RMTI | $1.53 0.99% 0.98% 32K
|
Health Technology
|
| O: 7.85%
H: 3.49%
C: -8.37%
fda phase 2 application trial
Viveve Announces Completion of Full Enrollment in Pivotal U.S. PURSUIT Trial for Stress Urinary Incontinence
Published: 2021-12-14 (Crawled : 14:00) - ir.viveve.com
VIVE | $0.0003 59900.0% 150
|
Health Technology
|
| O: -6.54%
H: 4.78%
C: 1.4%
trial enroll
Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa
Published: 2021-12-14 (Crawled : 13:30) - oramed.com
ORMP A | $2.39 2.58% 2.51% 31K
|
Health Technology
|
| O: -3.6%
H: 1.87%
C: -2.4%
covid-19 trial covid phase 1 vaccine enroll phase 2 africa
Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris
Published: 2021-12-14 (Crawled : 13:30) - biospace.com/
CABA | $13.31 -0.08% -0.08% 760K
|
Health Technology
|
| O: -40.86%
H: 1.15%
C: -52.81%
trial topline
Actinium Pharmaceuticals, Inc. Reports 2 Remissions and 67% ORR in Patients with a TP53 Mutation in the Phase 1 portion of the Actimab-A Venetoclax Combination Trial in Patients with Relapsed or Refractory AML at the 63rd ASH Annual Meeting
Published: 2021-12-14 (Crawled : 13:30) - biospace.com/
ATNM | $6.96 -2.93% -1.14% 190K
|
Health Technology
|
| O: -4.84%
H: 2.03%
C: -7.27%
tp53 als trial phase 1 aml
atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia
Published: 2021-12-14 (Crawled : 13:00) - biospace.com/
ATAI | $1.97 5.35% 5.08% 1.2M
|
Manufacturing
|
| O: -2.67%
H: 0.0%
C: 0.0%
rl-007 phase 2 schizophrenia air trial life science biomarkers phase 2b
KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX”
Published: 2021-12-14 (Crawled : 12:30) - globenewswire.com
KMPH | $5.46 6.04% 0
|
Manufacturing
|
| O: -9.75%
H: 3.23%
C: -0.91%
trial results topline
TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-14 (Crawled : 12:30) - globenewswire.com
TGTX | $14.25 1.06% 1.05% 3.2M
|
Health Technology
|
| O: -5.49%
H: 2.43%
C: -2.68%
ema trial therapeutics phase 3
Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection
Published: 2021-12-14 (Crawled : 12:30) - globenewswire.com
ABUS | $2.74 3.79% 3.65% 1.1M
|
Health Technology
|
| O: -2.52%
H: 7.76%
C: -2.59%
ati-2173 phase 2 hepatitis biopharma ab-729 trial therapeutics infection infections phase 2b chronic hepatitis b
Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
Published: 2021-12-14 (Crawled : 12:30) - biospace.com/
IMUX | $1.25 1.63% 1.6% 200K
|
Health Technology
|
| O: -3.49%
H: 1.75%
C: -6.36%
imu-935 trial positive results phase 1 potential positive results
Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial
Published: 2021-12-14 (Crawled : 12:30) - biospace.com/
ATHE | $2.14 0.47% 0.47% 32K
|
Health Technology
|
| O: 0.24%
H: 3.2%
C: 0.42%
ath434 phase 2 trial therapeutics authorization
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-14 (Crawled : 06:00) - biospace.com/
ATRA | $0.7199 3.23% 3.13% 830K
|
Health Technology
|
| O: -4.53%
H: 4.22%
C: 2.01%
cel ema trial therapeutics positive results tab-cel positive results phase 3 iot
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.